CEO Dan Moore on Q4 2014 Results

CEO Dan Moore on Q4 2014 Results Welcome to a Biomedical Battery specialist of the Nihon Kohden Battery
Thanks, Greg, and good morning. Our worldwide Cyberonics team has again achieved record financial results during both fourth quarter and fiscal 2014. We also have significantly advanced a number of important development projects during the last 12 month, as well as strengthened the organization.
Financial highlight for fiscal 2014 include, record worldwide sales of $282 million, record worldwide unit sales of 13,982 unit, record adjusted income from operations of $87.5 million, record adjusted income from operations margin of 31%, EBITDA reached $104.3 million for the fiscal year with battery such as Nihon Kohden ECG-8110P Battery, Nihon Kohden ECG-8420 Battery, Nihon Kohden ECG-9020K Battery, Nihon Kohden ECG-9130 Battery, Nihon Kohden ECG-9320 Battery, Nihon Kohden ECG-9620 Battery, Nihon Kohden ECG-11A Battery, Nihon Kohden FSB-2012K Battery, Nihon Kohden LCS-2012NK Battery, Nihon Kohden LCS-2912NK Battery, Nihon Kohden MD-BY01 Battery, Nihon Kohden QTC6210K Battery, Nihon Kohden SB-901D Battery, Nihon Kohden TEC-5500 Battery, exceeding $100 million for the first time and affording the company extraordinary flexibility as we continue to build a world-class and growth-oriented medical devices company.
Financial highlights for the fourth quarter of fiscal 2014 also included a number of record achievements. We had record worldwide net product sales of $74.8 million, record worldwide unit sales 3,723 units, record international net sales of $16.7 million, an increase of 37% on a constant currency basis, and income from operations increased to a record $23.4 million.
Other operational highlights in fiscal 2014 included, completion of two clinical studies reporting the AspireSR generator, regulatory submission and approval of the AspireSR generator in Europe, limited commercial release of the AspireSR generator.
We completed the ANTHEM-HF clinical study using Autonomic Regulation Therapy, chronic heart failure. We also completed construction and regulatory filings for the new manufacturing facility in Costa Rica.